GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase 1 study, the addition of GIPR activity to GLP-1R/GCGR co-agonism was reported to greatly potentiate the weight-lowering and glycemic efficacy in overweight subjects (NCT04521738)153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, GIPR agonism within multi-receptor agonists, improves bone metabolism153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, GIP may enhance some of the effects of GLP-1 receptor agonism.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development, and are illustrated by tirzepatide”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“patients with T2DM, while GIP is almost inactive (4).”
BackgroundSelf-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 3×
“Around 1992, Raufman and Eng in New York characterized the Gila monster peptide exendin-4 (18), which turned out to be a full agonist for the GLP-1 receptor (19) (a synthetic version of which, exenatide, reached the market in 2005 (20)).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Indeed, in 2002, mice with a knockout of the GIP receptor were demonstrated to be resistant to the adipogenic effect of a high-fat diet (42), and human genetic studies identified inactivating (Rosenkilde et al, unpublished) mutations in the GIP receptor, which were associated with weight loss (43).”
BackgroundSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“erance—their contribution (via insulin secretion) to postprandial glucose clearance may be as great as to correspond to 80% of the ingested amount of glucose (1).”
Background
Research works printed but not linked: 2
- Stensen S, Gasbjerg LS, Krogh LL, et al. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific effects in obese patients with type 2 diabetes. Diabetologia. 2019; 62: S270- S271.
- Marks V GIP: the obesity hormone. In: James WPT, Parker SW, eds. Current Approaches: Obesity. Southampton, England: Duphar Medical Relations; 1988: 13- 19.
Cited by
Items 201–208 of 208
Ferreira, M. H. L., Câmara, L. C., Mattoso, S. O., Pereira, S. I. D. S., de Aguiar, D. R., & Khan, Z. U. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02580-9
“GLP-1 enhances glucose-dependent insulin secretion, delays gastric emptying, and promotes central satiety, whereas GIP exerts complementary effects on insulin secretion and adipose tissue metabolism [10, 11].”
Wiater, D., Szkodziński, K., Jakubczyk, I., Maternia, J., Los, A. P. M., Majowicz-Czaszyńska, K. B., Pempuś, W., Król, N., Tomaszek, B., Blok, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5814
Pirfenidone restores metabolic hormones and cardiac autophagy via p-AMPK in MASH
López-Cifuentes, D., Sandoval-Rodriguez, A. S., Escutia-Gutiérrez, R., Armendáriz‐Borunda, J., & Gutiérrez‐Cuevas, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08828-1
“Glucose-dependent insulinotropic polypeptide (GIP) (secreted by the gut) stimulates insulin secretion after meals and facilitates fat storage in adipose tissue [4].”
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
“27,29 GIP's impact on appetite is currently debated.”
de Souza, P. F., Patriani, G., & Pacheco, C. M. R. (2026) · Cureus · doi:10.7759/cureus.116779
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“In type 2 diabetes, the incretin effect is markedly diminished: GIP retains plasma concentrations but loses much insulinotropic action with only partial recovery on glycemic correction (31, 33, 34), whereas GLP-1 retains insulin-stimulating activity.”
Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
Pages, L., Rojo, D., Jiménez-Masip, A., Tricarico, E., Mas‐Carrió, E., Aguilar, A., Gómez, N., Molinero, L., & Pericas, J. M. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102477 · Cited by 1
BindingDB Entry 50022803: Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
BindingDB (2026) · UC San Diego · doi:10.7270/q2028xcf
Metadata
- Authors
- Holst, J. J., & Rosenkilde, M. M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens Juul
- Rosenkilde, Mette Marie
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-05-27
- Volume
- 105
- Issue
- 8
- Pages
- e2710-e2716
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7308078
- OpenAlex
- W3030023482
- Cited by
- 207
- References
- 60
- Citations by year
- 2026: 32 · 2025: 36 · 2024: 39 · 2023: 28 · 2022: 40 · 2021: 26 · 2020: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, type 2 diabetes, obesity, GIP receptor antagonist, receptor internalization, ligand structure, insulin secretion, weight loss treatment, receptor signaling
- MeSH terms
- Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.